What’s inside
View ResearchDiscover how soluble antigen arrays (SAgAs) enhance the safety and efficacy of peptide-based immunotherapy for autoimmune diabetes. This study highlights SAgAs' superiority over free peptides in preventing diabetes, increasing regulatory T cells, and reducing anaphylaxis risk in the NOD mouse model. The findings suggest promising advancements for targeted autoimmune therapies using modified peptides.
Enhancing Peptide Immunotherapy with Soluble Antigen Arrays
Exploring the use of soluble antigen arrays to improve peptide-based immunotherapy for autoimmune diseases.
Safety and Efficacy of Soluble Antigen Arrays
Study on the efficacy and safety improvements of soluble antigen arrays compared to free peptides.
Mechanisms of Action in Peptide-Based Immunotherapy
Detailed analysis of how soluble antigen arrays influence immune responses and prevent autoimmune diabetes.
Peptide Modifications and Anaphylaxis
Examining how different peptide modifications affect the incidence and severity of anaphylaxis in immunotherapy.
Comparative Analysis of Peptide Delivery Modalities
Comparison of hydrolysable and non-hydrolysable soluble antigen arrays versus free peptides in treating autoimmune diseases.
Regulatory T Cell Induction by Soluble Antigen Arrays
Insights into how soluble antigen arrays induce regulatory T cells and improve immunotherapy outcomes.